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Abstract
Introduction Hypoxia-inducible factor (HIF)-1α levels in invasive
breast carcinoma have been shown to be an adverse prognostic
indicator. Cellular HIF-1α activity is regulated by factor-inhibiting
hypoxia-inducible factor 1 (FIH-1). In hypoxia, FIH-1
hydroxylation of Asn803 within the C-terminal transactivation
domain does not occur and HIF-1α forms a fully active
transcriptional complex. The present study investigates the role
of FIH-1 in invasive breast carcinoma and its correlation with
hypoxia.
Methods Microarrayed tissue cores from 295 invasive
carcinomas were stained for FIH-1, for HIF-1α and for carbonic
anhydrase 9. FIH-1 expression was correlated with standard
clinicopathological parameters and with the expression of the
surrogate hypoxic markers HIF-1α and carbonic anhydrase 9.
Results FIH-1 was positive in 239/295 (81%) tumours, 42/295
(14%) exclusively in the nucleus and 54/295 (18%) exclusively
in the cytoplasm. Exclusive nuclear FIH-1 expression was
significantly inversely associated with tumour grade (P = 0.02)
and risk of recurrence (P  = 0.04), whereas exclusive
cytoplasmic FIH-1 was significantly positively associated with
tumour grade (P = 0.004) and carbonic anhydrase 9 expression
(P = 0.02). Patients with tumours that excluded FIH-1 from the
nucleus had a significantly shorter survival compared with those
with exclusive nuclear expression (P = 0.02). Cytoplasmic FIH-
1 expression was also an independent poor prognostic factor
for disease-free survival.
Conclusion FIH-1 is widely expressed in invasive breast
carcinoma. As with other HIF regulators, its association between
cellular compartmentalization and the hypoxic response and
survival suggests that tumour regulation of FIH-1 is an additional
important mechanism for HIF pathway activation.
Introduction
Regions of hypoxia are common in breast carcinoma [1,2] as
the rate of nutrient and oxygen delivery is often insufficient to
meet the high metabolic demands of neoplastic cells. The neo-
plastic cells can adapt to this hostile microenvironment using
the activation of hypoxia-induced genes for angiogenesis, gly-
colysis and other processes advantageous to cell proliferation
and survival. The activation of these hypoxia-induced genes
centres on the levels of hypoxia-inducible factor (HIF) 1 within
the tumour cell [3]. HIF-1 is a heterodimer, consisting of a HIF-
1α subunit and a HIF-1β subunit. While HIF-1β is constitu-
tively expressed, HIF-1α levels are tightly regulated with rapid
upregulation and degradation [4].
It is therefore not surprising that HIF-1α has been identified in
breast tumours and is frequently implicated in altering their
behaviour. Tumour cells in perinecrotic regions of ductal carci-
noma in situ lesions, where HIF-1α levels are high, exhibit a
CA9 = carbonic anhydrase 9; CI = confidence interval; ER = oestrogen receptor; FIH-1 = factor-inhibiting hypoxia-inducible factor 1; H & E = hae-
matoxylin and eosin; HER2 = human epidermal growth factor receptor 2; HIF = hypoxia-inducible factor; HR = hazard ratio; OR = odds ratio; PBS = 
phosphate-buffered saline; PHD = prolyl hydroxylase domain; TAD = transcriptional activation domain.Breast Cancer Research    Vol 9 No 6    Tan et al.
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more aggressive phenotype, with loss of differentiation and
downregulation of oestrogen-receptor (ER) expression [5,6].
High HIF-1α expression has been demonstrated to be an
adverse prognostic indicator, being associated with reduced
disease-free survival and overall survival [7,8], and also with an
increased risk of metastasis and early recurrence [9].
HIF-1α levels are modulated by post-translational hydroxyla-
tion that is dependent on cellular oxygen levels. Two mecha-
nisms involving members of the Fe(II) and 2-oxoglutarate-
dependent dioxygenases have been described to date. The
prolyl hydroxylase domain enzymes (PHD1, PHD2 and PHD3)
catalyse the hydroxylation of conserved proline residues P402
and P564 within the oxygen-dependent degradation domain
(part of the N-terminal transcriptional activation domain (TAD))
of HIF-1α [10,11]. This facilitates HIF-1α recognition by Von-
Hippel-Lindau protein and subsequent degradation by the E3
ubiquitin ligase complex [12,13]. In the absence of cellular
oxygen and hydroxylation, HIF-1α subunits are not targeted for
proteasome degradation and are able to translocate into the
nucleus, where they associate with the HIF-1β subunit. Subse-
quent recruitment of a number of cofactors including p300,
with the C-terminal TAD of HIF-1α [14-16], enables formation
of the fully active transcriptional complex.
Factor-inhibiting hypoxia-inducible factor 1 (FIH-1) gives a fur-
ther level of control. FIH-1 catalyses the hydroxylation of a con-
served asparagine residue Asn803 within the C-terminal TAD
under normoxic conditions [17,18]. FIH-1 interaction at the C-
terminal TAD associates with Von-Hippel-Lindau protein
bound at the N-terminal TAD to form a ternary complex that
blocks p300 interaction, resulting in repression of C-terminal
TAD activity [19]. It has been postulated further that PHD
hydroxylation of the conserved proline resides within the N-ter-
minal TAD facilitates Von-Hippel-Lindau protein binding that in
turn promotes FIH-1 recruitment to the C-terminal TAD, where
it hydroxylates the conserved asparagine residue [20].
In normoxia, therefore, PHD and FIH-1 enzymes act synergis-
tically to degrade and inactivate HIF-1α, restricting HIF-1α
activity within the cell to a minimum. As cellular oxygen levels
decrease, the PHD enzymes have limited oxygen for hydroxy-
lation and no longer hydroxylate the N-terminal TAD, leading to
stabilization and accumulation of the HIF-1α subunit [10,11].
Nevertheless, FIH-1 remains active at this stage and continues
to repress C-terminal TAD activity until conditions of severe
hypoxia occur, where FIH-1 also fails to hydroxylate the aspar-
agine residue in the C-terminal TAD and releases C-terminal
TAD repression [21,22]. This graded response to increasingly
severe hypoxia suggests that FIH-1 may have a crucial func-
tion as one of the final checks on HIF-1α transcriptional
activity.
We have previously demonstrated that FIH-1 is strongly
expressed in both the luminal epithelial cells and myoepithelial
cells in the normal breast [23]. FIH-1 expression was mostly
cytoplasmic, with some weak nuclear staining in a proportion
of cells. Breast carcinoma cells showed not only strong
expression of FIH-1 in the cytoplasm, but in the nucleus as well
[23]. FIH-1 expression was also noted in nonepithelial ele-
ments, such as stromal fibroblastic cells, vascular smooth
muscle cells and infiltrating inflammatory cells.
To better understand the regulation of HIF-1α in breast carci-
noma, we have examined the expression of FIH-1 in a large
characterized series of breast carcinomas and have correlated
this with standard clinicopathological parameters and various
markers of hypoxia. In view of the significant upregulation of
FIH-1 expression within the nucleus of tumour cells compared
with normal breast tissues, we have also analysed the FIH-1
expression in these two subcellular compartments separately.
The subcellular localization of FIH-1 was found to be associ-
ated with differing prognostic significance. Tumours express-
ing FIH-1 exclusively within the nucleus were associated with
low tumour grade and a reduced risk of recurrence, while
tumours expressing FIH-1 only in the cytoplasm were more
likely to express carbonic anhydrase 9 (CA9) and were asso-
ciated with high tumour grade and poor disease-free survival.
Materials and methods
Patient and tumour characteristics
Microarrayed tissue 1 mm cores from 295 invasive breast car-
cinomas were collected from patients who underwent surgery
at the John Radcliffe Hospital, Oxford, UK. Four separate
cores were obtained from each tumour specimen; necrotic
regions were avoided. The present study has Ethical Commit-
tee approval (number C02.216). Cores that were incomplete
or that did not include tumour epithelial cells were excluded.
Only patients with operable breast carcinoma were included in
the study. No participants had received any neoadjuvant ther-
apy. Information of the patient characteristics, including age,
tumour size, tumour grade, histology, nodal status, ER status
and human epidermal growth factor receptor 2 (HER2) status,
were collected from clinical and pathological records. The
median age of the patients was 57 years (range, 29–90
years).
Seventy-one per cent of invasive tumours were classified as
invasive ductal carcinoma of no specific type, 7% as invasive
lobular carcinoma, and 8% as other histological types (data
were unavailable for the remaining 14% of tumours). The
median tumour grade according to the Bloom and Richardson
criteria was 2, and the median tumour size was 20 mm (range,
2–230 mm). Forty-three per cent of tumours were node-posi-
tive, 77% were ER-positive and 13% were HER2-positive.
Patients younger than 50 years of age with node-positive or
ER-negative tumours or with tumours >3 cm in size were given
adjuvant chemotherapy (cyclophosphamide, methotrexate and
5-fluorouracil). Patients with hormone-responsive tumoursAvailable online http://breast-cancer-research.com/content/9/6/R89
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who were older than 50 years of age were given endocrine
therapy. Over a median follow-up period of 105 months
(range, 5.1–161.2 months), there were 108 relapses and 114
breast cancer-related deaths.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections (4 μm) of
microarrayed invasive carcinomas were dewaxed in citroclear
and were rehydrated in graduated ethanol solutions. Endog-
enous peroxidase activity was blocked with 0.5% hydrogen
peroxide for 30 minutes, and nonspecific binding with 2.5%
normal horse serum for 20 minutes. The respective primary
antibodies FIH-1 antibody (clone FIH162c, mouse IgG2k mon-
oclonal antibody; Nuffield Department of Clinical Laboratory
Sciences, Oxford, UK) [23], CA9 antibody (clone M75; gift
from J Pastorek, Institute of Virology, Slovak Republic) [24],
and HIF-1α antibody (clone ESEE 122, mouse monoclonal
IgG1; Nuffield Department of Clinical Laboratory Sciences)
[25] were then applied at room temperature. Antibody details
are presented in Table 1. Substitution of the primary antibody
with PBS served as a negative control. Transfected COS-1
cells expressing FIH-1 were used as a positive control. The pri-
mary antibody was followed by application of the Envision kit
secondary antibody (Dako A/S, Glostrup, Denmark) for 30
minutes, and the peroxidase reaction was developed using
diaminobenzidine provided in the kit. The slides were then
counterstained in H & E and mounted in aqueous mountant.
HER2 staining was assessed with the Hercept test kit (Dako
A/S).
Scoring was performed by two observers simultaneously. The
level of staining for FIH-1 was scored with respect to the per-
centage of cells expressing the protein and the intensity of
staining in both the nucleus and cytoplasm. The scoring sys-
tem for intensity was: 0, no staining; 1, weak staining; 2, mod-
erate staining; and 3, strong staining. The scoring system for
the percentage of cells was: 0, no cells staining positive; 1,
<10% cells staining positive; 2, 11–50% positive cells; 3, 51–
80% positive cells; and 4, >80% positive cells.
Tumours with an intensity score ≥2 and a percentage score ≥1
were considered positive in the statistical analysis. Although
some cytoplasmic staining was also observed in tumours
stained with HIF-1α, only tumours demonstrating any nuclear
staining were considered positive in the analysis. Cytoplasmic
HIF-1α staining was assessed in relation to FIH-1 expression;
tumours expressing HIF-1α in the cytoplasm with intensity ≥2
were considered positive in this analysis. We have previously
shown that tissue microarrays are representative of the whole
tissue section for HIF-1α evaluation [26].
There is no general consensus for CA9 regarding a cutoff
threshold, and various authors have used different cutoff
thresholds [27-29]. Since a cutoff threshold of 10% is com-
monly used for many clinical markers, such as ER and proges-
terone receptor status [30,31], we considered tumours
demonstrating membranous staining in ≥10% of cells to be
positive in the analysis.
Statistical methods
Correlation between FIH-1 in a particular subcellular compart-
ment, the other hypoxic markers as well as the various clinico-
pathological parameters were evaluated using either the chi-
square test or Fisher's exact test where appropriate. Correla-
tion with tumour grade was evaluated using the chi-square test
for trend. Kaplan–Meier survival curves were calculated using
tumour recurrence (defined as the first reappearance of a
tumour at any site following definitive treatment) as the end-
point. Disease-free survival between groups was compared
using a log-rank test. All univariate and survival analyses were
performed with GraphPadPrism version 4 (GraphPad Soft-
ware Inc., San Diego, CA, USA).
In addition, the Cox proportional hazard regression model was
used to identify independent prognostic factors for disease-
free survival. This was carried out using the Stata Package
release 8.1 (Stata Corporation, College Station, TX, USA). A
full model was first created to include all potentially important
explanatory variables. At each step, the variable with the small-
est contribution to the model was removed, until a final back-
Table 1
Details of primary antibodies used
Antibody Details of antibody Antigen retrieval Dilution Incubation period 
(hours)
Reference
Factor-inhibiting hypoxia-
inducible factor 1 
(FIH162c)
Mouse monoclonal IgG2k 
(Nuffield Department of Clinical 
Laboratory Sciences, Oxford, UK)
None Neat supernatant 1.5 [23]
Hypoxia-inducible factor 
1α (ESEE122)
Mouse monoclonal IgG1 (Nuffield 
Department of Clinical Laboratory 
Sciences)
Pressure cook for 3 min 
in ethylenediamine 
tetraacetic acid, pH 8.0
1:100 4 [24]
Carbonic anhydrase 9 
(M75)
Mouse monoclonal (from J. 
Pastorek, Institute of Virology, 
Slovak Republic)
None 1:50 0.5 [25]Breast Cancer Research    Vol 9 No 6    Tan et al.
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ward stepwise model was obtained. A two-tailed test was
used in all analyses and P < 0.05 was considered statistically
significant.
Results
Factor-inhibiting hypoxia-inducible factor-1 expression 
in invasive breast carcinoma
FIH-1 was widely expressed among the invasive breast carci-
nomas analysed (Figure 1). Eighty-one per cent of tumours
(239/295) stained positive for FIH-1, either in the cytoplasm,
in the nucleus or in both compartments (Table 2). FIH-1
showed strong expression in the cytoplasm of a large propor-
tion of tumour cells, with a median cytoplasmic intensity of 2
and a median percentage of more than 80% of cells. Nineteen
per cent of tumours (56/295) were negative for FIH-1. The
majority of the tumours (48.5%) expressed FIH-1 both in the
cytoplasm as well as in the nucleus. FIH-1 was expressed
exclusively in the cytoplasm in 18% (54/295) of tumours, and
exclusively in the nucleus in 14% (42/295) of tumours (Table
2). Nuclear FIH-1 expression had a median nuclear intensity of
2 and a median percentage of 50–80% of cells.
Apart from the tumour epithelial cells, FIH-1 was also widely
expressed in nonepithelial elements within the tumours. FIH-1
was expressed in the stroma of 78% of tumours, in the vascu-
lature of 81% of tumours and in the infiltrating inflammatory
cells in 74% of tumours.
Correlation of factor-inhibiting hypoxia-inducible factor 
1 with clinicopathological parameters and hypoxia 
markers
Any nuclear FIH-1 expression was inversely associated with
tumour grade (P = 0.02). Exclusive nuclear FIH-1 expression
Table 2
Subcellular location of factor-inhibiting hypoxia-inducible factor 1 in tumour cells
Subcellular location Number (%) of cores
Present in cytoplasm only 54 (18%)
Present in nucleus only 42 (14%)
Present in both cytoplasm and nucleus 143 (48%)
Negative for factor-inhibiting hypoxia-inducible factor 1 56 (19%)
Figure 1
Immunohistochemistry of factor-inhibiting hypoxia-inducible factor 1 in breast carcinomas Immunohistochemistry of factor-inhibiting hypoxia-inducible factor 1 in breast carcinomas. (a) Negative tumour staining. (b) Weak tumour 
cytoplasmic and nuclear staining. (c) Strong tumour nuclear staining. (d) Strong tumour cytoplasmic staining.Available online http://breast-cancer-research.com/content/9/6/R89
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was also significantly inversely associated with tumour grade
(P = 0.02). Nuclear FIH-1 expression was not significantly
associated with patient age, tumour size, nodal status, ER or
HER2 status (P > 0.05) (Table 3). Any cytoplasmic or exclu-
sive cytoplasmic FIH-1 expression was significantly positively
associated with tumour grade (P  = 0.05 and P  = 0.004,
respectively). There was no significant correlation between
any cytoplasmic or exclusive cytoplasmic FIH-1 expression
and patient age, tumour size, nodal status, ER and HER2 sta-
tus (P > 0.05) (Table 3).
Any nuclear FIH-1 expression was inversely correlated with
CA9 expression (P = 0.04), with tumours negative for CA9
also being twice as likely to express FIH-1 within the nucleus
(P = 0.04, odds ratio (OR) = 2.22, 95% confidence interval
(CI) = 0.21–0.96) (Table 3). No significant correlation was
observed between exclusive nuclear FIH-1 expression and
CA9 (P = 0.43). Exclusive cytoplasmic FIH-1 expression, how-
ever, was significantly associated with CA9 expression (P =
0.02, OR = 2.65, 95% CI = 1.17–6.02) (Table 3).
The relationship between FIH-1 and HIF-1α was also
assessed. Nuclear FIH-1 expression showed a significant pos-
itive correlation with nuclear HIF-1α expression, being twice
as likely to be expressed in HIF-1α-positive tumours (P  =
0.004, OR = 2.11, 95% CI = 1.26–3.52) (Table 4). There was
no significant correlation between nuclear FIH-1 expression
and cytoplasmic HIF-1α expression (P = 0.68). Cytoplasmic
Table 3
Clinicopathological parameters of the series of 295 invasive breast carcinomas together with correlation analyses of cytoplasmic 
and nuclear factor-inhibiting hypoxia-inducible factor-1 (FIH-1) expression
Exclusive nuclear FIH-1 
expression (n = 42)
Nuclear and cytoplasmic 
FIH-1 expression (n = 143)
Exclusive cytoplasmic FIH-
1 expression (n = 54)
Nuclear and cytoplasmic 
FIH-1-negative (n = 56)
Median patient age (years) 57 56 58 56
Median tumour size (mm) 18 20 25 20
Tumour grade
11 2 2 4 3 8
21 2 4 3 1 7 1 5
3 8 35 21 12
Nodal status
Negative 23 77 32 35
Positive 19 64 22 20
Oestrogen receptor status
Negative 8 30 14 20
Positive 34 113 40 35
Human epidermal growth 
factor receptor 2 status
Negative 25 95 43 23
Positive 3 17 6 2
Hypoxia-inducible factor 1α
Negative 10 41 25 22
Positive 32 82 28 20
Carbonic anhydrase 9
Negative 34 111 33 22
Positive 3 14 11 4
Recurrence
Negative 32 88 28 37
Positive 9 54 26 18
n < 295 data not available.Breast Cancer Research    Vol 9 No 6    Tan et al.
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FIH-1 expression was significantly associated with cytoplas-
mic HIF-1α expression (P = 0.03, OR = 2.25, 95% CI = 1.06–
4.75) but not with nuclear HIF-1α expression (Table 4).
Correlation of hypoxia-inducible factor 1α with 
clinicopathological parameters and survival
Although HIF-1α expression did not correlate with tumour size,
tumour grade or ER and HER2 status, tumours expressing
HIF-1α were twice as likely to be associated with nodal dis-
ease (P = 0.02, OR = 1.91, 95% CI = 1.09–3.33) (Table 5).
HIF-1α-expressing tumours were also associated with a signif-
icantly shorter disease-free survival (P = 0.04, HR = 1.60,
95% CI = 1.02–2.42) (Figure 2a).
Correlation of factor-inhibiting hypoxia-inducible factor 
1 with survival
Tumours with cytoplasmic FIH-1 expression were associated
with a significantly worse prognosis than FIH-1 cytoplasmic-
negative tumours (P = 0.04, HR = 1.57, 95% CI = 1.01–
2.26), with a 1.8-fold increase in the risk of recurrence (P =
0.03, OR = 1.8, 95% CI = 1.04–2.99) (Figure 2b and Table
3). Tumours demonstrating nuclear FIH-1 expression showed
a longer survival than those without nuclear expression (Figure
2c) but this did not reach statistical significance (P = 0.24,
95% CI = 0.53–1.17). Since this observation suggested that
cytoplasmic translocation of FIH-1 from the nucleus abrogated
the antagonistic effect of FIH-1, we examined the relationship
Table 4
Univariate analysis of nuclear and cytoplasmic factor-inhibiting hypoxia-inducible factor 1 (FIH-1) expression with hypoxia-
inducible factor 1α (HIF-1α) expression
Nuclear FIH-1-
positive (n = 186)
Nuclear FIH-1-
negative (n = 109)
P value Cytoplasmic FIH-1-
positive (n = 197)
Cytoplasmic FIH-1-
negative (n = 98)
P value
Nuclear HIF-1α 0.004 0.93
Negative 52 48 66 32
Positive 114 50 110 52
Cytoplasmic HIF-1α 0.68 0.03
Negative 129 72 130 68
Positive 33 21 43 10
n < 295 data not available.
Table 5
Correlation analysis of hypoxia-inducible factor 1α (HIF-1α) expression and standard clinicopathological parameters
HIF-1α-positive (n = 125) HIF-1α-negative (n = 91) P value
Median patient age (years) 59 59 0.59
Median tumour size (mm) 20 20 0.23
Tumour grade 0.52
12 2 1 5
24 4 2 2
32 7 2 3
Nodal status 0.02
Negative 62 31
Positive 63 60
Oestrogen receptor status 0.90
Negative 98 72
Positive 27 19
Human epidermal growth factor receptor 2 status 0.77
Negative 12 11
Positive 87 70
n < 216 data not available.Available online http://breast-cancer-research.com/content/9/6/R89
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Figure 2
Kaplan–Meier curves of disease-free survival Kaplan–Meier curves of disease-free survival. (a) Stratifying patients by hypoxia-inducible factor-1α (HIF-1α) expression. (b) Stratifying patients 
by cytoplasmic factor-inhibiting hypoxia-inducible factor-1 (FIH-1) expression. (c) Stratifying patients by nuclear FIH-1 expression. (d) Stratifying 
patients by exclusive nuclear FIH-1 expression (functional), and by exclusive cytoplasmic FIH-1 expression and FIH-1 negativity (nonfunctional). (e) 
Stratifying patients by exclusive cytoplasmic FIH-1 expression (nonfunctional), and by exclusive nuclear FIH-1 expression (functional). (f) Stratifying 
patients by exclusive cytoplasmic FIH-1 expression and tumours negative for FIH-1.Breast Cancer Research    Vol 9 No 6    Tan et al.
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among potentially functional (conserving nuclear expression)
and nonfunctional (no nuclear expression) FIH-1 and survival.
When stratifying tumours as nonfunctional (exclusive cytoplas-
mic and no FIH-1 expression) and as functional (retained
nuclear expression), the group of patients with nonfunctional
FIH-1 had a significantly shorter survival than those who
retained FIH-1 in the nucleus (P = 0.02, HR = 0.42, 95% CI
= 0.27–0.89) (Figure 2d).
Patients with tumours expressing FIH-1 exclusively in the cyto-
plasm had a significantly shorter disease-free survival com-
pared with those expressing FIH-1 exclusively in the nucleus
(P = 0.007, HR = 0.37, 95% CI = 0.21–0.78) (Figure 2e).
Patients with tumours exclusively expressing FIH-1 within the
nucleus had a significantly reduced risk of recurrence (P =
0.04, OR = 2.27, 95% CI = 0.20–0.96). Although not signifi-
cant, patients with tumours that expressed FIH-1 exclusively in
the cytoplasm demonstrated a shorter relapse-free survival
than those tumours negative for FIH-1 (P = 0.12, 95% CI =
0.88–2.88) (Figure 2f).
When adding FIH-1 expression to standard clinicopathologi-
cal factors of tumour grade, size and nodal status in multivari-
ate analysis, neither nuclear nor cytoplasmic FIH-1 expression
showed significant prognostic predictive value to the model (P
= 0.11 and P  = 0.14, respectively). Using the same base
model, however, exclusive cytoplasmic FIH-1 expression was
found to be an independent poor prognostic factor for dis-
ease-free survival, with a HR of 1.73 (P = 0.04, 95% CI =
1.04–2.89) (Table 6). Conversely, exclusive nuclear FIH-1
expression was associated with a longer disease-free survival
(HR = 0.43, 95% CI = 0.17–1.08), although this was of bor-
derline significance (P = 0.07) (Table 7).
Discussion
In the present study we have demonstrated frequent expres-
sion of FIH-1 in the neoplastic cells of invasive breast carcino-
mas, with only approximately 20% of tumours being FIH-1-
negative. FIH-1 was also expressed in the non-neoplastic
tumour elements, suggesting a possible role in regulating HIF-
1α activity in these cell populations. To the best of our knowl-
edge there is limited data on the factors that regulate FIH-1,
but it would be of interest to assess whether protein kinase
Cζ, which has been shown to inhibit FIH-1 mRNA synthesis in
renal cell carcinomas [32], also regulates FIH-1 expression in
breast cancer.
In accordance with other studies, we observed expression of
FIH-1 within the cytoplasm and nucleus of tumour cells
[23,33,34]. This neoplastic cell localization was significantly
associated with the phenotype of the tumour – with nuclear
and cytoplasmic location being positively correlated with low
and high tumour grade, respectively, and cytoplasmic FIH-1
also being associated with CA9 expression. This association
suggests that nuclear FIH-1 accounts for the C-terminal TAD
repression and thus leads to a reduction in HIF-1α activity. The
molecular weight of FIH-1 (40.3 kDa) enables it to shuttle
between cellular compartments by passive diffusion [35]. The
corollary of this thesis is that FIH-1 is actively excluded from
the nucleus by tumours with an aggressive phenotype. Fur-
thermore, since there is frequent loss of chromosome 10q24
in breast cancer where the FIH-1 gene resides [36,37], loss
of FIH-1 protein expression may occur through further muta-
tion or epigenetic alterations in the remaining FIH-1 gene, as
has been reported in high-grade gliomas [38]. Mutation of
other HIF-1α-modifying enzymes, including prolyl hydroxylase
2 [39], have also been reported in endometrial tumours.
The regulation of HIF-1α has profound influence on the clinical
outcome. High HIF-1α levels are correlated with high-grade
tumours [40] and are associated with early widespread meta-
static disease and survival [9]. In the present study, HIF-1α
expression was positively correlated with nodal disease and a
shorter disease-free survival. Although FIH-1 may indirectly
affect HIF-1α levels through modulation of the PHD2 and
PHD3 genes [33], FIH-1 primarily modulates HIF-1α activity
rather than its level of expression [34]. This explains our obser-
vation that nuclear FIH-1 expression is positively correlated
with HIF-1α expression, since FIH-1 is not involved in the deg-
radation of HIF-1α. Interestingly, FIH-1 appeared to be associ-
ated with HIF-1α regardless of its subcellular location,
although the significance of its association with FIH-1 in the
cytoplasm is not clear.
Table 7
Multivariate analysis Cox regression model of disease-free survival for standard clinicopathological parameters and exclusive 
nuclear factor-inhibiting hypoxia-inducible factor expression (n = 209)
Hazard ratio 95% confidence interval P value
Exclusive nuclear factor-inhibiting hypoxia-inducible factor 1 0.43 0.17–1.08 0.07
Tumour grade 1.54 1.09–2.17 0.01
Tumour size 2.89 1.76–4.76 <0.001
Nodal status 2.70 1.65–4.42 <0.001Available online http://breast-cancer-research.com/content/9/6/R89
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As FIH-1 is able to modulate HIF-1α activity, it would be
expected to affect tumour behaviour in a similar manner. Our
finding that nuclear and cytoplasmic FIH-1 expression is
associated with a reduced risk and an increased risk of recur-
rence, respectively, is in keeping with hydroxylation of HIF-1α
in the nuclear compartment, thereby interfering with coactiva-
tor binding through the CH-1 domain of p300. We have used
subset analysis to assess the potential effects of FIH-1 on out-
come because of the clear differences in expression patterns
that are likely to be functionally important. Indeed, we have pre-
viously shown that breast cancer using this compartmentaliza-
tion process to enhance coactivator recruitment for
cytoplasmic localization of CBP/p300-interacting transactiva-
tor (CITED) -4, a new member of the CITED family that can
compete with HIF-1α for p300, has a worse prognosis [41]. In
an analogous manner, inhibiting FIH-1 through translocation to
the cytoplasmic compartment would allow an enhanced
hypoxic response mediated through HIF-1α.
The above findings suggest that modulation of FIH-1 would be
a powerful mechanism to reduce the HIF response. This is a
particularly attractive target since, unlike the prolyl hydroxy-
lases, FIH-1 can reduce HIF-1α activity over a range of oxygen
tensions and even in severely hypoxic conditions [21,33].
Agents targeting FIH-1 would therefore further complement
the repertoire of therapeutic agents aimed at inhibiting HIF-1α
activity in tumours. Proof of principle for the potential of such
intervention is shown by amphotericin B, a commonly used
treatment for systemic mycoses, which enhances the interac-
tion between HIF-1α C-terminal TAD and FIH-1, thereby
blocking p300 recruitment and suppressing hypoxia-induced
erythropoietin production [42]. It is likely that the repressive
signals mediated by FIH-1 go beyond that of changing the HIF
response since FIH-1 has recently been shown to hydroxylate
the IκB family at specific asparaginyl residues that are con-
served but present in a range of ankyrin repeat domains [43].
These data demonstrate the potential of FIH-1 to modulate the
clinical outcome in tumours.
Conclusion
In the present study we have demonstrated a widespread
expression of FIH-1 among invasive breast carcinomas, with
particular subcellular locations of FIH-1 being associated with
prognosis. Our findings suggest the value of further studies to
investigate the mechanism of nuclear localization of FIH-1 and
how it can be manipulated to target the HIF-1α pathway and
other pathways in breast cancer therapy.
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